Chemical Name:2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amin
o]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoq
uinolinecarboxylic acid hydrochloride
Biological Activity:
Angiotensin-converting enzyme (ACE) inhibitor
that is hydrolysed in the liver to the active metabolite moexiprilat (IC50
values are 2.1 and 2700 nM for moexiprilat and moexipril respectively).
Antihypertensive; decreases mean blood pressure in the spontaneous hypertensive
rat (SHR). Also blocks degradation of bradykinin into inactive metabolites.
Edlinget al
(1995) Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor:
pharmacological characterization and comparison with enalapril.
J.Pharmacol.Exp.Ther. 275 854. Friehe and Ney (1997)
Pharmacological and toxicological studies of the new angiotensin converting
enzyme inhibitor moexipril hydrochloride. Arzneim.-Forsch. 47
132. Chrysant and Chrysant (2004) Pharmacological and clinical profile
of moexipril: a concise review. J.Clin.Pharmacol. 44 827.
Inhibitor of dipeptidyl peptidase IV (DPP-IV) (IC50 = 104 nM) that displays selectivity over enzymes with DPP-like activity (IC50 > 30 μM). Increases plasma GLP-1 levels and improves glucose tolerance in diabetic mice following oral glucose challenge.
